THC for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

THC for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

THC's firmest uses are narrow: calming the nausea and vomiting of cancer treatment, and restoring appetite lost to illness. Nerve pain and muscle stiffness relief is real but modest, with unwanted effects about as common. Harms are clearer: faster heart rate, less flexible blood vessels, hours of impaired judgment, difficulty stopping. (Full Review)

Protocol

Standard clinical protocol
0.5–2.5 mg, evening
Once daily; escalation in 0.5–2.5 mg increments every 2–7 days to the lowest effective dose, typically 2.5–20 mg daily
Best time of day
1–3 h before sleep
Standard for oral preparations; daytime dosing is confined to low-dose, cannabidiol-dominant preparations
Single dose versus split dosing
Single evening dose
Split dosing only where daytime spasticity or breakthrough pain requires it; it raises cumulative exposure and tolerance
Time to effect
Oral onset
30 min to 3 h
Peak at 2–4 hours; the delay is the most common cause of accidental overconsumption
Inhaled onset
5–10 min
Peak at 15–30 minutes
Pain and spasticity
1–2 weeks
Consistent dosing before benefit can be assessed; early doses are dominated by side effects that attenuate

Benefits

Contraindications
  • Personal or first-degree family history of schizophrenia, schizoaffective or bipolar I disorder
  • Pregnancy at any stage and throughout lactation
  • History of cannabinoid hyperemesis syndrome
  • Regular use under approximately 25 years of age
  • Myocardial infarction within 90 days, unstable angina, New York Heart Association Class III–IV heart failure, uncontrolled arrhythmia or hypertension above 160/100 mmHg
  • Child-Pugh Class B or C hepatic impairment
  • Safety-sensitive occupations with workplace testing; athletes under World Anti-Doping Agency testing
Key Interactions
  • Central nervous system depressants (alcohol, opioids, benzodiazepines, gabapentinoids)
  • CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, grapefruit juice)
  • CYP3A4 inducers (rifampicin, carbamazepine, St John's wort)
  • CYP2C9 inhibitors and substrates (fluconazole, amiodarone, warfarin)
  • Cannabidiol-containing products
  • Over-the-counter medications (sedating antihistamines, dextromethorphan, anticholinergics)
  • Supplement interactions (valerian, kava, melatonin, glycine, piperine, bergamot)
  • Additive-effect supplements (dietary nitrate, arginine, hibiscus, caffeine)
  • Other intervention interactions (sauna and heat, psychedelics, fasting, anaesthesia)

Risk & Side Effects

  • High: Acute cognitive and psychomotor impairment; dependence and withdrawal; acute cardiovascular strain; psychotic symptoms and psychotic illness; anxiety, panic, and dysphoria; increased motor vehicle collision risk; sedation and dry mouth
  • Medium: Impaired endothelial function and vascular ageing; cannabinoid hyperemesis syndrome; respiratory injury from smoked and vaporised routes; reduced semen quality and reproductive hormone disruption; persistent cognitive deficits with sustained heavy use; depressed mood and suicidal behaviour
  • Low: Disruption of rapid eye movement sleep; orthostatic hypotension and falls in older adults; reduced training motivation and exercise output; testicular germ cell tumour association
  • Speculative: Accelerated cognitive ageing and dementia risk; reduced bone mineral density

Monitoring

Marker Target Why
Resting heart rate 50–65 bpm Tachycardia is the most consistent physiological effect
Seated blood pressure <120/75 mmHg Baseline; detects contraindicating hypertension
Postural blood pressure drop <10 mmHg systolic on standing Detects orthostatic hypotension driving dizziness and falls
Flow-mediated dilation >8% Most sensitive early marker of endothelial injury
High-sensitivity C-reactive protein (hs-CRP) <0.5 mg/L Tracks systemic and smoke-related airway inflammation
Fasting insulin 2–5 µIU/mL Visceral fat and insulin sensitivity shift at stable weight
Haemoglobin A1c (HbA1c) 4.8–5.4% Downstream effect of the appetite and intake changes
Alanine aminotransferase (ALT) 10–26 U/L (men), 10–19 U/L (women) Clearance is hepatic; impairment raises exposure
Total testosterone (men) 600–900 ng/dL Acute luteinising hormone suppression; hormonal disruption
Luteinising hormone (LH) 2–8 IU/L (men) Separates central axis suppression from gonadal causes
Sperm concentration >40 million/mL Most consistently reduced parameter; reversible on cessation
Bone mineral density (T-score) > -1.0 Addresses the speculative skeletal signal
12-lead electrocardiogram (ECG) Normal sinus rhythm, QTc <440 ms (men) / <460 ms (women) Screens for the arrhythmia signal in registry data

Cadence: Baseline within 4 weeks of starting; symptom and side-effect review at 1 and 4 weeks after initiation or dose change; vitals at 4 weeks; full panel at 6 months, then every 6–12 months; vascular and bone assessment every 12–24 months

Qualitative Assessment

  • Sleep quality on drug-free nights — whether unassisted sleep has worsened
  • Morning cognitive clarity — a consistent task at the same time daily
  • Training output — session volume, load, and perceived exertion
  • Symptom control against baseline — the target symptom, scored consistently
  • Craving and control — unplanned use, difficulty with drug-free days
  • Mood and anxiety — including anxiety occurring between doses
  • Appetite pattern — unplanned caloric intake after dosing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.